<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03489616</url>
  </required_header>
  <id_info>
    <org_study_id>SDCH201701LC</org_study_id>
    <nct_id>NCT03489616</nct_id>
  </id_info>
  <brief_title>Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients</brief_title>
  <acronym>CRAGMOLC</acronym>
  <official_title>Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients Without Progression After First-line Chemotherapy: a Prospective Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Cancer Hospital and Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether chemotherapy combination with local
      radiotherapy and rhGM-CSF is safe, effective in the treatment of oligometastatic stage IV
      NSCLC patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether chemotherapy combination with local
      radiotherapy and recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF)
      is safe, effective in the treatment of oligometastatic stage IV NSCLC patients who were PR or
      SD after first-line chemotherapy，and to observe the abscopal effect, whether the scheme can
      improve PFS and OS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-Free-Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abscopal effect rate</measure>
    <time_frame>At the time point of 4 weeks after completion of rhGM-CSF</time_frame>
    <description>Radiotherapy-induced immune-mediated tumour regression at sites distant to the irradiated field</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Radiotherapy+chemotherapy+ rhGM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with PR or SD after first-line chemotherapy will be treated with pemetrexed on d1 (500mg/m2) or other single agent on d1, d8. Local radiotherapy dose will be＞ 4Gy per time（or BED ＞45Gy） from day 2 to day 15 in a cycle of 21 days. Subcutaneous injection of rhGM-CSF (200ug/m² per day) will be executed 24 hours after chemotherapy. Repeat in the second metastatic lesions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single agent maintenance therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maintenance treatment by single agent in a cycle of 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rhGM-CSF</intervention_name>
    <description>rhGM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils. rhGM-CSF can promote the maturation of dendritic cells and macrophage, increase their antigen presentation ability.</description>
    <arm_group_label>Radiotherapy+chemotherapy+ rhGM-CSF</arm_group_label>
    <other_name>Recombinant human granulocyte macrophage stimulating factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.</description>
    <arm_group_label>Radiotherapy+chemotherapy+ rhGM-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Local Radiotherapy</intervention_name>
    <description>Radiotherapy promotes the release of tumor antigen</description>
    <arm_group_label>Radiotherapy+chemotherapy+ rhGM-CSF</arm_group_label>
    <other_name>Local Radiation therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single agent</intervention_name>
    <description>Other chemotherapy drugs,such as Docetaxel, gemcitabine</description>
    <arm_group_label>Radiotherapy+chemotherapy+ rhGM-CSF</arm_group_label>
    <arm_group_label>Single agent maintenance therapy</arm_group_label>
    <other_name>Single agent for maintenance therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Stage IV NSCLC patients without clear driving genes who were PR or SD after standard
             first-line chemotherapy;

          2. Patients who were oligometastasis evaluated by PET-CT or other examinations after
             first-line chemotherapy. Eligible patients should have 2 to 5 distant metastases (at
             least 2 metastases were suitable for low fractionated radiotherapy). At least one
             distant measurable lesion outside the radiation sites.

          3. Age varied from 18 to 75 years old.

          4. ECOG performance status 0-2.

          5. Expected lifespan ≥3 months.

          6. Absolute neutrophil count (ANC) ≥1.5×109/L, Platelets ≥100×109/L, Hemoglobin ≥90 g/L.

          7. Able to understand and give written informed consent and comply with study procedures.

        Exclusion criteria

          1. Allergy of rhGM-CSF and its accessories.

          2. Disease of systemic immune or immune disorders.

          3. Histology confirmed small cell carcinoma or other malignant compositions in the cancer
             tissue.

          4. Patients with thrombotic disease or platelets ≥600×109/L

          5. Cancer history within 5 years apart from NSCLC before enrollment.

          6. Tumor related immunotherapy within 4 weeks, including but not limited to immune cell
             therapy, tumor vaccine therapy, Immune checkpoint therapy, and other immunomodulators
             (such as thymosin, lentinan) except for rhGM-CSF.

          7. The abnormality of kidney , heart or lung functions（serum creatinine, Cr&gt;177mol/L;
             serum AST or ALT more than 2 times above normal limits; total bilirubin,
             TBIL&gt;34mol/L）.

          8. HIV virus, hepatitis C virus or T lymphocyte virus (type1 or type 2) infection and
             active hepatitis or other uncontrolled infections.

          9. Women in pregnancy or lactation.

         10. Others who do not meet the inclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JINMING YU, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Cancer Hospital and Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Huan Li, doctor</last_name>
    <phone>131 5303 5389</phone>
    <email>sy_lmh2001@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>JINMING YU, doctor</last_name>
    <phone>13806406293</phone>
    <phone_ext>0531-87984729</phone_ext>
    <email>jn7984729@public.jn.sd.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shandong Cancer Hospital and Institute</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MINGHUAN LI, Doctor</last_name>
      <phone>13153035389</phone>
      <phone_ext>0531-67626112</phone_ext>
      <email>Sy_lmh2001@163.com</email>
    </contact>
    <contact_backup>
      <last_name>JIMING YU, Doctor</last_name>
      <phone>13806406293</phone>
      <phone_ext>0531-87984729</phone_ext>
      <email>jn7984729@public.jn.sd.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>SHANDONG Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, Friedman K, Ponzo F, Babb JS, Goldberg J, Demaria S, Formenti SC. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015 Jul;16(7):795-803. doi: 10.1016/S1470-2045(15)00054-6. Epub 2015 Jun 18.</citation>
    <PMID>26095785</PMID>
  </results_reference>
  <results_reference>
    <citation>Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec;17(12):1672-1682. doi: 10.1016/S1470-2045(16)30532-0. Epub 2016 Oct 24.</citation>
    <PMID>27789196</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>April 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2018</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Cancer Hospital and Institute</investigator_affiliation>
    <investigator_full_name>Jinming Yu</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

